Articles by tag: efgartigimod

Vyvgart approved for all serotypes of myasthenia gravis

FDA expanded Vyvgart indications to all patients with generalized myasthenia gravis. Learn how this will change the treatment market. Read analysis.

FDA approved Vyvgart for all serotypes of myasthenia gravis

FDA approved efgartigimod (Vyvgart) for all serotypes of gMG, including seronegative patients. Learn how this will change the market and what it means for you. Read the detailed analysis.